Metformine Zydus

Metformin Hydrochloride, the active ingredient in Metformine Zydus, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus and to improve overall glycemic control.

GNH USA supplies Metformine Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance across EU and global markets. The company maintains robust logistics where required and provides full documentation for import and distribution.

Metformin Hydrochloride is used in the management of disorders related to glucose metabolism, particularly type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle modification. - Polycystic ovary syndrome: helps restore ovulatory cycles and reduces hyperinsulinemia in affected women.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset that often resolves with continued therapy. - Diarrhea: loose stools, usually occurring early in treatment. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a potentially life‑threatening accumulation of lactate, requiring immediate medical attention. - Severe hypoglycemia: uncommon when used alone but possible with concomitant insulin or sulfonylureas. - Hepatotoxicity: rare liver enzyme elevations. - Skin reactions: such as rash or Stevens‑Johnson syndrome. - Vitamin B12 deficiency: long‑term use may reduce absorption leading to anemia.

When prescribing Metformin Hydrochloride, clinicians should consider several safety precautions to minimize risks. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic disease: avoid in patients with significant liver impairment due to lactic acidosis risk. - Cardiovascular status: use cautiously in patients with unstable heart failure. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Concomitant medications: review for drugs that may affect renal clearance or increase metformin levels. - Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Metformin Hydrochloride interacts with several medicines that can alter its plasma concentration or increase the risk of adverse events.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: may raise metformin plasma levels, heightening toxicity. - Renally cleared drugs (e.g., trimethoprim): combined use can impair metformin excretion.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazide diuretics: can affect glucose control. - Alcohol: excessive intake raises lactic acidosis risk. - Oral contraceptives: may slightly increase metformin concentrations.